卵巢内富血小板血浆注射对卵巢低反应患者体外受精结局的影响:双盲随机对照试验
这项安慰剂对照双盲随机试验纳入60例POSEIDON 3/4组卵巢低反应患者,首次取卵时随机接受卵巢内富血小板血浆注射或安慰剂,连续三次卵巢刺激取卵。
要点
- 富血小板血浆组临床妊娠率低于对照组(27% vs 60%,P=0.018),整倍体囊胚数无差异。
- 富血小板血浆注射对获卵数有益作用的机制尚不明确,需进一步研究确认。
核心结论
- 卵巢内富血小板血浆注射增加卵巢低反应患者获卵数,但未提高发育囊胚的质量,且未证实改善整倍体囊胚发育或妊娠率。
研究设计与样本
- 安慰剂对照、双盲、随机对照试验,纳入60例按POSEIDON分类3组和4组分层的卵巢低反应患者,年龄30-42岁,等比例随机分入治疗组或对照组。
- 患者计划接受三次连续卵巢刺激以累积卵母细胞,于第一次取卵时接受富血小板血浆或安慰剂注射,第三次卵巢穿刺后行卵胞浆内单精子注射。
- 采用计算机生成的随机码进行随机化,双盲确保受试者和研究者均不知晓分组。
主要发现
- 所有患者成熟卵母细胞数随取卵次数增加:第一次穿刺2.61±0.33,第二次3.85±0.42,第三次4.73±0.44;治疗组增幅更大。
- 第二次穿刺获成熟卵母细胞数治疗组4.18±0.58 vs 对照组3.27±0.61(差值95%CI -0.30至2.12,P=0.138);第三次穿刺治疗组5.27±0.73 vs 对照组4.15±0.45(差值95%CI 0.12-2.12,P=0.029)。
- 发育并活检的囊胚数(均值±标准误)对照组2.43±0.60 vs 治疗组1.90±0.32(P=0.449);整倍体囊胚数对照组0.81±0.24 vs 治疗组0.81±0.25(P=1.000)。
- 有整倍体囊胚的患者比例对照组53.33%(16/30) vs 治疗组43.33%(13/30)(Fisher精确检验P=0.606);按意向性分析总妊娠率43%(26/60),临床妊娠率对照组60%(18/30) vs 治疗组27%(8/30)(P=0.018),足月妊娠治疗组有更差趋势(P=0.170),分娩方式和新生儿性别两组无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 富血小板血浆注射对获卵数潜在有益作用的机制未知,可能涉及释放的血小板因子或机械效应。
- 需要进一步研究以确认或反驳本试验数据,并明确富血小板血浆制剂的确切作用机制(如有)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does platelet-rich plasma (PRP) intraovarian injection increase the number of retrieved oocytes in successive ovarian punctions among patients with poor ovarian reserve (POR)? SUMMARY ANSWER: The injection of PRP increases the number of retrieved oocytes without increasing the quality of developed blastocysts. WHAT IS KNOWN ALREADY: Management of women with reduced ovarian response to stimulation is one of the significant challenges in reproductive medicine. Recently, PRP treatment has been proposed as an adjunct in assisted reproduction technology, with controversial results. STUDY DESIGN, SIZE, DURATION: This placebo-controlled, double-blind, randomized trial included 60 patients with POR stratified according to the POSEIDON classification groups 3 and 4. It was conducted to explore the efficacy and safety of intraovarian PRP injection. Patients were proposed to undergo three consecutive ovarian stimulations to accumulate oocytes and were randomized to receive either PRP or placebo during their first oocyte retrieval. Randomization was performed using computer-generated randomization codes. Double blinding was ensured so that neither the participant nor the investigators knew of the treatment allotted. All patients underwent three ovarian stimulations and egg retrieval procedures. ICSI was performed after a third ovarian puncture. The primary endpoint was the number of mature oocytes retrieved after PRP or placebo injection in successive ovarian punctures. PARTICIPANTS/MATERIALS, SETTING, METHODS: Sixty women (30-42 years) fulfilling inclusion criteria were randomized in equal proportions to the treatment or control groups. MAIN RESULTS AND THE ROLE OF CHANCE: The baseline demographic and clinical characteristics [age, BMI, anti-Müllerian hormone (AMH) levels] were comparable between the groups. Regarding the primary endpoint, the cumulative number (mean ± SEM) of retrieved mature oocytes was slightly higher in the treatment group: 10.45 ± 0.41 versus 8.91 ± 0.39 in the control group, respectively (95% CI of the difference 0.42-2.66; P = 0,008). The number of mature oocytes obtained among all patients increased in successive egg retrievals: 2.61 ± 0.33 (mean ± SEM) in punction 1 (P1), 3.85 ± 0.42 in P2, and 4.73 ± 0.44 in P3. However, the increase was higher among patients receiving the assessed PRP treatment. In P2, the number of retrieved mature oocytes was 4.18 ± 0.58 versus 3.27 ± 0.61 in controls (95% CI of the difference: -0.30 to 2.12; P = 0.138) and in P3, 5.27 ± 0.73 versus 4.15 ± 0.45 (95% CI of the difference: 0.12-2.12; P = 0.029). The mean ± SEM number of developed and biopsied blastocysts was 2.43 ± 0.60 in the control group and 1.90 ± 0.32 in the treatment group, respectively (P = 0.449). The mean number of euploid blastocysts was 0.81 ± 0.24 and 0.81 ± 0.25 in the control and treatment groups, respectively (P = 1.000). The percentages of patients with euploid blastocysts were 53.33% (16 out of 30) and 43.33% (13 out of 30) for patients in the control and treatment groups, respectively (Fisher's exact test P = 0.606). The overall pregnancy rate per ITT was 43% (26 out of 60 patients). However, the percentage of clinical pregnancies was higher in the control group (18 out of 30, 60%) than in the treatment group (8 out of 30, 27%) (P = 0.018). There was also a trend toward poorer outcomes in the treatment group when considering full-term pregnancies (P = 0.170). There were no differences between control and treatment groups regarding type of delivery, and sex of newborns. LIMITATIONS, REASONS FOR CAUTION: The mechanism of the potential beneficial effect of PRP injection on the number of retrieved oocytes is unknown. Either delivered platelet factors or a mechanical effect could be implicated. Further studies will be needed to confirm or refute the data presented in this trial and to specify the exact mechanism of action, if any, of PRP preparations. WIDER IMPLICATIONS OF THE FINDINGS: The increasing number of women with a poor response to ovarian stimulation supports the exploration of new areas of research to know the potential benefits of therapies capable of increasing the number of oocytes available for fertilization and improving the quality of developed blastocysts. An increase in the retrieved oocytes in both arms of the trial suggests that, beyond the release of growth factor from platelets, a mechanical effect can play a role. However, neither improvement in euploid blastocyst development nor pregnancy rates have been demonstrated. STUDY FUNDING/COMPETING INTEREST(S): This trial was supported by Basque Government and included in HAZITEK program, framed in the new Euskadi 2030 Science and Technology Plan (PCTI 2030). These aids are co-financed by the European Regional Development Fund (FEDER). The study funders had no role in the study design, implementation, analysis, manuscript preparation, or decision to submit this article for publication. No competing interests are declared by all the authors. TRIAL REGISTRATION NUMBER: Clinical Trial Number EudraCT 2020-000247-32. TRIAL REGISTRATION DATE: 3 November 2020. DATE OF FIRST PATIENT’S ENROLLMENT: 16 January 2021.
引用
- Barrenetxea G, Celis R, Barrenetxea J, et al. Intraovarian platelet-rich plasma injection and IVF outcomes in patients with poor ovarian response: a double-blind randomized controlled trial. Hum Reprod. 2024. PMID: 38423539. doi:10.1093/humrep/deae038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。